Research ExplorerPublicationsAssessing the impact of COVID-19 on liver cancer management ...

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Standard

Assessing the impact of COVID-19 on liver cancer management (CERO-19). / Muñoz-Martínez, Sergio; Sapena, Victor; Forner, Alejandro; Nault, Jean-Charles; Sapisochin, Gonzalo; Rimassa, Lorenza; Sangro, Bruno; Bruix, Jordi; Sanduzzi-Zamparelli, Marco; Hołówko, Wacław; El Kassas, Mohamed; Mocan, Tudor; Bouattour, Mohamed; Merle, Philippe; Hoogwater, Frederik J H; Alqahtani, Saleh A; Reeves, Helen L; Pinato, David J; Giorgakis, Emmanouil; Meyer, Tim; Villadsen, Gerda Elisabeth; Wege, Henning; Salati, Massimiliano; Mínguez, Beatriz; Di Costanzo, Giovan Giuseppe; Roderburg, Christoph; Tacke, Frank; Varela, María; Galle, Peter R; Alvares-da-Silva, Mario Reis; Trojan, Jörg; Bridgewater, John; Cabibbo, Giuseppe; Toso, Christian; Lachenmayer, Anja; Casadei-Gardini, Andrea; Toyoda, Hidenori; Lüdde, Tom; Villani, Rosanna; Matilla Peña, Ana María; Guedes Leal, Cassia Regina; Ronzoni, Monica; Delgado, Manuel; Perelló, Christie; Pascual, Sonia; Lledó, José Luis; Argemi, Josepmaria; Basu, Bristi; da Fonseca, Leonardo; Acevedo, Juan; Siebenhüner, Alexander R; Braconi, Chiara; Meyers, Brandon M; Granito, Alessandro; Sala, Margarita; Rodríguez Lope, Carlos; Blaise, Lorraine; Romero-Gómez, Manuel; Piñero, Federico; Gomez, Dhanny; Mello, Vivianne; Pinheiro Alves, Rogerio Camargo; França, Alex; Branco, Fernanda; Brandi, Giovanni; Pereira, Gustavo; Coll, Susanna; Guarino, Maria; Benítez, Carlos; Anders, Maria Margarita; Bandi, Juan C; Vergara, Mercedes; Calvo, Mariona; Peck-Radosavljevic, Markus; García-Juárez, Ignacio; Cardinale, Vincenzo; Lozano, Mar; Gambato, Martina; Okolicsanyi, Stefano; Arraez, Dalia Morales; Elvevi, Alessandra; Muñoz, Alberto E; Lué, Alberto; Iavarone, Massimo; Reig, Maria.

In: JHEP REP, Vol. 3, No. 3, 100260, 06.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Muñoz-Martínez, S, Sapena, V, Forner, A, Nault, J-C, Sapisochin, G, Rimassa, L, Sangro, B, Bruix, J, Sanduzzi-Zamparelli, M, Hołówko, W, El Kassas, M, Mocan, T, Bouattour, M, Merle, P, Hoogwater, FJH, Alqahtani, SA, Reeves, HL, Pinato, DJ, Giorgakis, E, Meyer, T, Villadsen, GE, Wege, H, Salati, M, Mínguez, B, Di Costanzo, GG, Roderburg, C, Tacke, F, Varela, M, Galle, PR, Alvares-da-Silva, MR, Trojan, J, Bridgewater, J, Cabibbo, G, Toso, C, Lachenmayer, A, Casadei-Gardini, A, Toyoda, H, Lüdde, T, Villani, R, Matilla Peña, AM, Guedes Leal, CR, Ronzoni, M, Delgado, M, Perelló, C, Pascual, S, Lledó, JL, Argemi, J, Basu, B, da Fonseca, L, Acevedo, J, Siebenhüner, AR, Braconi, C, Meyers, BM, Granito, A, Sala, M, Rodríguez Lope, C, Blaise, L, Romero-Gómez, M, Piñero, F, Gomez, D, Mello, V, Pinheiro Alves, RC, França, A, Branco, F, Brandi, G, Pereira, G, Coll, S, Guarino, M, Benítez, C, Anders, MM, Bandi, JC, Vergara, M, Calvo, M, Peck-Radosavljevic, M, García-Juárez, I, Cardinale, V, Lozano, M, Gambato, M, Okolicsanyi, S, Arraez, DM, Elvevi, A, Muñoz, AE, Lué, A, Iavarone, M & Reig, M 2021, 'Assessing the impact of COVID-19 on liver cancer management (CERO-19)', JHEP REP, vol. 3, no. 3, 100260. https://doi.org/10.1016/j.jhepr.2021.100260

APA

Muñoz-Martínez, S., Sapena, V., Forner, A., Nault, J-C., Sapisochin, G., Rimassa, L., Sangro, B., Bruix, J., Sanduzzi-Zamparelli, M., Hołówko, W., El Kassas, M., Mocan, T., Bouattour, M., Merle, P., Hoogwater, F. J. H., Alqahtani, S. A., Reeves, H. L., Pinato, D. J., Giorgakis, E., ... Reig, M. (2021). Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP REP, 3(3), [100260]. https://doi.org/10.1016/j.jhepr.2021.100260

Vancouver

Muñoz-Martínez S, Sapena V, Forner A, Nault J-C, Sapisochin G, Rimassa L et al. Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP REP. 2021 Jun;3(3). 100260. https://doi.org/10.1016/j.jhepr.2021.100260

Bibtex

@article{9d54bbe9d0d64daa9d1db5f4a9340ce6,
title = "Assessing the impact of COVID-19 on liver cancer management (CERO-19)",
abstract = "Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.",
author = "Sergio Mu{\~n}oz-Mart{\'i}nez and Victor Sapena and Alejandro Forner and Jean-Charles Nault and Gonzalo Sapisochin and Lorenza Rimassa and Bruno Sangro and Jordi Bruix and Marco Sanduzzi-Zamparelli and Wac{\l}aw Ho{\l}{\'o}wko and {El Kassas}, Mohamed and Tudor Mocan and Mohamed Bouattour and Philippe Merle and Hoogwater, {Frederik J H} and Alqahtani, {Saleh A} and Reeves, {Helen L} and Pinato, {David J} and Emmanouil Giorgakis and Tim Meyer and Villadsen, {Gerda Elisabeth} and Henning Wege and Massimiliano Salati and Beatriz M{\'i}nguez and {Di Costanzo}, {Giovan Giuseppe} and Christoph Roderburg and Frank Tacke and Mar{\'i}a Varela and Galle, {Peter R} and Alvares-da-Silva, {Mario Reis} and J{\"o}rg Trojan and John Bridgewater and Giuseppe Cabibbo and Christian Toso and Anja Lachenmayer and Andrea Casadei-Gardini and Hidenori Toyoda and Tom L{\"u}dde and Rosanna Villani and {Matilla Pe{\~n}a}, {Ana Mar{\'i}a} and {Guedes Leal}, {Cassia Regina} and Monica Ronzoni and Manuel Delgado and Christie Perell{\'o} and Sonia Pascual and Lled{\'o}, {Jos{\'e} Luis} and Josepmaria Argemi and Bristi Basu and {da Fonseca}, Leonardo and Juan Acevedo and Siebenh{\"u}ner, {Alexander R} and Chiara Braconi and Meyers, {Brandon M} and Alessandro Granito and Margarita Sala and {Rodr{\'i}guez Lope}, Carlos and Lorraine Blaise and Manuel Romero-G{\'o}mez and Federico Pi{\~n}ero and Dhanny Gomez and Vivianne Mello and {Pinheiro Alves}, {Rogerio Camargo} and Alex Fran{\c c}a and Fernanda Branco and Giovanni Brandi and Gustavo Pereira and Susanna Coll and Maria Guarino and Carlos Ben{\'i}tez and Anders, {Maria Margarita} and Bandi, {Juan C} and Mercedes Vergara and Mariona Calvo and Markus Peck-Radosavljevic and Ignacio Garc{\'i}a-Ju{\'a}rez and Vincenzo Cardinale and Mar Lozano and Martina Gambato and Stefano Okolicsanyi and Arraez, {Dalia Morales} and Alessandra Elvevi and Mu{\~n}oz, {Alberto E} and Alberto Lu{\'e} and Massimo Iavarone and Maria Reig",
note = "{\textcopyright} 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).",
year = "2021",
month = jun,
doi = "10.1016/j.jhepr.2021.100260",
language = "English",
volume = "3",
journal = "JHEP REP",
issn = "2589-5559",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Assessing the impact of COVID-19 on liver cancer management (CERO-19)

AU - Muñoz-Martínez, Sergio

AU - Sapena, Victor

AU - Forner, Alejandro

AU - Nault, Jean-Charles

AU - Sapisochin, Gonzalo

AU - Rimassa, Lorenza

AU - Sangro, Bruno

AU - Bruix, Jordi

AU - Sanduzzi-Zamparelli, Marco

AU - Hołówko, Wacław

AU - El Kassas, Mohamed

AU - Mocan, Tudor

AU - Bouattour, Mohamed

AU - Merle, Philippe

AU - Hoogwater, Frederik J H

AU - Alqahtani, Saleh A

AU - Reeves, Helen L

AU - Pinato, David J

AU - Giorgakis, Emmanouil

AU - Meyer, Tim

AU - Villadsen, Gerda Elisabeth

AU - Wege, Henning

AU - Salati, Massimiliano

AU - Mínguez, Beatriz

AU - Di Costanzo, Giovan Giuseppe

AU - Roderburg, Christoph

AU - Tacke, Frank

AU - Varela, María

AU - Galle, Peter R

AU - Alvares-da-Silva, Mario Reis

AU - Trojan, Jörg

AU - Bridgewater, John

AU - Cabibbo, Giuseppe

AU - Toso, Christian

AU - Lachenmayer, Anja

AU - Casadei-Gardini, Andrea

AU - Toyoda, Hidenori

AU - Lüdde, Tom

AU - Villani, Rosanna

AU - Matilla Peña, Ana María

AU - Guedes Leal, Cassia Regina

AU - Ronzoni, Monica

AU - Delgado, Manuel

AU - Perelló, Christie

AU - Pascual, Sonia

AU - Lledó, José Luis

AU - Argemi, Josepmaria

AU - Basu, Bristi

AU - da Fonseca, Leonardo

AU - Acevedo, Juan

AU - Siebenhüner, Alexander R

AU - Braconi, Chiara

AU - Meyers, Brandon M

AU - Granito, Alessandro

AU - Sala, Margarita

AU - Rodríguez Lope, Carlos

AU - Blaise, Lorraine

AU - Romero-Gómez, Manuel

AU - Piñero, Federico

AU - Gomez, Dhanny

AU - Mello, Vivianne

AU - Pinheiro Alves, Rogerio Camargo

AU - França, Alex

AU - Branco, Fernanda

AU - Brandi, Giovanni

AU - Pereira, Gustavo

AU - Coll, Susanna

AU - Guarino, Maria

AU - Benítez, Carlos

AU - Anders, Maria Margarita

AU - Bandi, Juan C

AU - Vergara, Mercedes

AU - Calvo, Mariona

AU - Peck-Radosavljevic, Markus

AU - García-Juárez, Ignacio

AU - Cardinale, Vincenzo

AU - Lozano, Mar

AU - Gambato, Martina

AU - Okolicsanyi, Stefano

AU - Arraez, Dalia Morales

AU - Elvevi, Alessandra

AU - Muñoz, Alberto E

AU - Lué, Alberto

AU - Iavarone, Massimo

AU - Reig, Maria

N1 - © 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

PY - 2021/6

Y1 - 2021/6

N2 - Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.

AB - Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.

U2 - 10.1016/j.jhepr.2021.100260

DO - 10.1016/j.jhepr.2021.100260

M3 - SCORING: Journal article

C2 - 33644725

VL - 3

JO - JHEP REP

JF - JHEP REP

SN - 2589-5559

IS - 3

M1 - 100260

ER -